These studies suggested that lung cancer cells with ’permanent’ NRF2-ARE activation due to weakened KEAP1 acquired multiple advantages for proliferation and resistance to chemotherapy promoting malignancy. The gene discussed is NFE2L2; the disease is lung cancer.